家族性地中海热与长期风湿免疫共病风险:全国性匹配队列研究
该研究基于以色列全国电子健康记录(2001–2024),纳入3324例确诊家族性地中海热(FMF)患者与13296例匹配对照,评估风湿及自身免疫共病的基线和长期累积发生。FMF与多种风湿免疫病持续相关,复合终点发生率为17.0%对7.4%(校正OR 2.18),提示即使使用秋水仙碱仍需长期风湿免疫监测。
要点
- FMF患者基线即与Behçet病、类风湿关节炎、纤维肌痛、痛风、骨关节炎及结缔组织病相关(q<0.05)。
- 随访期间FMF进一步与强直性脊柱炎、狼疮、血管炎、银屑病关节炎及克罗恩病相关(校正OR 1.31–12.7,q<0.05)。
- FMF复合风湿免疫终点发生率17.0%对7.4%,校正OR 2.18,淀粉样变性1.26%对0.015%(q<0.001)。
核心结论
- FMF与选择性、持续的风湿及自身免疫病超额风险相关,且该风险在秋水仙碱治疗背景下仍存在。
研究设计与样本
- 全国性、回顾性、基于人群的匹配队列研究,使用以色列Leumit健康服务电子健康记录(2001–2024),FMF患者与对照按年龄、性别和社会经济地位1:4匹配。
主要发现
- 基线时FMF与Behçet病、类风湿关节炎、纤维肌痛、痛风、骨关节炎及结缔组织病相关(均q<0.05)。
- 随访期间FMF进一步与强直性脊柱炎、狼疮、血管炎、银屑病关节炎及克罗恩病相关(校正OR 1.31–12.7,均q<0.05)。
- 淀粉样变性在FMF中显著更常见(1.26%对0.015%,q<0.001)。
- 复合终点在FMF中更高(17.0%对7.4%,校正OR 2.18)。
关键数值与推荐
- 共病识别采用ICD-9编码,评估基线患病率及最长20年累积发生率,设12个月洗脱期。
- 多变量logistic回归校正人口学及临床协变量,并采用错误发现率校正。
临床怎么用
- 对FMF患者应进行长期风湿免疫共病监测,即使正在接受秋水仙碱治疗。
局限性
- 回顾性研究设计及基于ICD编码识别共病可能引入错分偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Familial Mediterranean fever (FMF) is characterized by pyrin inflammasome dysregulation and chronic subclinical inflammation. Whether FMF carries an increased long-term burden of rheumatologic and autoimmune inflammatory disease is unclear. We evaluated baseline and long-term occurrence of rheumatologic and selected autoimmune comorbidities in FMF. METHODS: This was a nationwide, retrospective, population-based matched-cohort study using electronic health records from Leumit Health Services in Israel (2001-2024). Patients with confirmed FMF were matched 1:4 with controls by age, sex, and socioeconomic status. Rheumatologic and selected autoimmune comorbidities, including inflammatory bowel disease and autoimmune thyroid disease, were identified using International Classification of Diseases, 9th Revision (ICD-9) codes. Baseline prevalence and cumulative occurrence over up to 20 years were assessed, with a 12-month washout. A composite endpoint of any prespecified rheumatologic or autoimmune diagnosis was evaluated. Multivariable logistic regression was adjusted for demographic and clinical covariates, with false discovery rate correction. RESULTS: The cohort included 3324 FMF patients and 13,296 controls (mean age 24.5 years; 51% female). At baseline, FMF was associated with Behçet disease, rheumatoid arthritis, fibromyalgia, gout, osteoarthritis, and connective tissue disease (all q < 0.05). During follow-up, FMF was further associated with ankylosing spondylitis, lupus, vasculitis, psoriatic arthritis, and Crohn's disease (adjusted odds ratios 1.31-12.7; all q < 0.05). Amyloidosis was markedly more frequent in FMF (1.26%vs. 0.015%; q < 0.001). The composite endpoint was higher in FMF (17.0%vs. 7.4%; adjusted odds ratio 2.18). CONCLUSION: FMF is associated with a selective, persistent excess of rheumatologic and autoimmune diseases despite colchicine, supporting long-term rheumatologic surveillance.
引用
- Magen E, Aamar S, Magen I, et al. Long-term rheumatologic comorbidities in familial Mediterranean fever. Semin Arthritis Rheum. 2026. PMID: 42250404. doi:10.1016/j.semarthrit.2026.153016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。